Small cap regenerative medicine stock RepliCel Life Sciences (OTCQB: REPCF; CVE: RP) has just reported compelling safety and clinical data from its phase 1/2 tendon repair study investigating the use ofthe Companys type 1 collagen-expressing, hair follicle-derived fibroblasts (RCT-01) as a treatment for Achilles tendinosis. The clinical trial met its goal of establishing a complete safety profile at 6 months. More importantly, there wereno serious adverse events related to the study treatment or injection procedure.
Tendinosis, sometimes called chronic tendinitis, chronic tendinopathy....More>>>